Analysis of iron homeostasis and erythroid activity in a cohort of low-risk myelodysplastic patients

被引：0
|
作者：
Messa, E. [1 ]
Maffe, C. [1 ]
Volpe, G. [1 ]
Campostrini, N. [2 ]
Gioia, D. [3 ]
Carturan, S. [1 ]
Zanone, C. [1 ]
Levis, A. [3 ]
Cilloni, D. [1 ]
Girelli, D. [2 ]
Camaschella, C. [4 ]
Saglio, G. [1 ]
机构：
[1] Univ Turin, Orbassano, Italy
[2] Univ Verona, I-37100 Verona, Italy
[3] SS Arrigo & Biagio Hosp, Alessandria, Italy
[4] S Raffaele Inst, Milan, Italy
来源：
LEUKEMIA RESEARCH | 2009年 / 33卷
关键词：
D O I：
10.1016/S0145-2126(09)70167-5
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
[No abstract available]
引用
收藏
页码：S108 / S109
页数：2
相关论文
共 50 条
  • [21] A decision analysis to determine the appropriate treatment for low-risk myelodysplastic syndromes
    Sekeres, Mikkael A.
    Fu, Alex Z.
    Maciejewski, Jaroslaw R.
    Golshayan, Ali-Reza
    Kalaycio, Matt E.
    Kaftan, Michael W.
    CANCER, 2007, 109 (06) : 1125 - 1132
  • [22] Supportive therapy for low-risk myelodysplastic syndromes
    Gay, Julie
    HEMATOLOGIE, 2008, 14 (03): : 178 - 184
  • [23] rHuEpo treatment in low-risk myelodysplastic syndromes
    Grossi, A
    BRITISH JOURNAL OF HAEMATOLOGY, 1999, 106 (02) : 574 - 574
  • [24] Amifostine in the treatment of low-risk myelodysplastic syndromes
    Grossi, A
    Fabbri, A
    Santini, V
    Leoni, F
    Nozzoli, C
    Longo, G
    Pagliai, G
    Ciolli, S
    Ferrini, PR
    HAEMATOLOGICA, 2000, 85 (04) : 367 - 371
  • [25] Erythroid Activity, Transfusion Iron Overload, and Hepcidin Levels in Patients with Myelodysplastic Syndrome.
    Malcovati, Luca
    Della Porta, Matteo G.
    Laarakkers, Coby M.
    Galli, Anna
    Albertini, Riccardo
    Maffioli, Margherita
    Ambaglio, Ilaria
    Travaglino, Erica
    Invernizzi, Rosangela
    Moratti, Remigio
    Swinkels, Dorine W.
    Cazzola, Mario
    BLOOD, 2008, 112 (11) : 925 - 925
  • [26] Erythropoietin for the anemia of low-risk myelodysplastic syndromes
    Fenaux, P
    Ades, L
    BLOOD, 2005, 106 (03) : 768 - 769
  • [27] Overall Survival and Erythroid Response in Patients with Low-Risk Myelodysplastic Neoplasms after First-Line Treatment in a Low-Middle Income Country
    Burgos, Sebastian
    Ontiveros-Austria, Juan
    Rodriguez-Rodriguez, Sergio
    Apodaca Chavez, Elia Ixel
    BLOOD, 2023, 142
  • [28] The IRON2 Study. A Retrospective Observational Study to Describe the Evolution of Iron Overload in Patients with Low-Risk Myelodysplastic Syndrome
    Remacha, Angel
    Arrizabalaga, Beatriz
    Villegas, Ana
    Soledad Duran, Maria
    Hermosin, Lourdes
    de Paz, Raquel
    Garcia, Marta
    Garcia, Regina
    del Canizo, Consuelo
    Sanz, Silvia
    Sanz, Guillermo
    BLOOD, 2012, 120 (21)
  • [29] THE COST OF BLOOD TRANSFUSION IN LOW-RISK PATIENTS WITH MYELODYSPLASTIC SYNDROMES (MDS): AN ECONOMIC ANALYSIS FOR THE CASE OF GREECE
    Fragoulakis, B.
    Maniadakis, N.
    Panagiotidis, P.
    HAEMATOLOGICA, 2012, 97 : 145 - 146
  • [30] LOW-RISK MYELODYSPLASTIC PATIENTS SUPPORTED WITH ERYTHROPOIETIN PLUS LIPOSOMIAL IRON SHOWS A REDUCED NUMBER OF FEBRILE EPISODES THAN PATIENTS WITH INTRAVENOUS IRON SUPPORT
    Giordano, G.
    Berardi, D.
    Commatteo, A.
    D'Amico, F.
    Verdecampo, A.
    Traficante, D.
    Carabellese, B.
    Licianci, A.
    Di Marzio, L.
    Berardi, G.
    Gigli, R.
    Magri, M.
    Niro, G.
    Di Lullo, L.
    HAEMATOLOGICA, 2015, 100 : 70 - 71
12345